Everything below concerns lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Styrene can be obtained in one stage if this reaction is conducted at elevated temperatures (315–440 °C (599–824 °F)) and pressures (0.35–0.7 MPa (51–102 psi)), in presence of an aluminosilicate catalyst.
He is also related to Leonard Wolfson, Baron Wolfson, Miel de Botton and Janet Wolfson de Botton, Trustee of Tate and Chairman of the Council of Tate Modern and appointed Commander of the Most Excellent Order of the British Empire (CBE) in 2006 and elevated to Dame Commander of the Order of the British Empire (DBE) in the 2013 Birthday Honours for charitable services to the arts. Caryl Brahms writer Julius Braunthal (1891–1972) was an Austrian Jewish historian, magazine editor, and political activist; Secretary of the Socialist International from 1951 to 1956; wrote three volume History of the International, first published in German between 1961 and 1971. David Bret biographer, broadcaster and chansonnier (French-born; Jewish father) Jacob Bronowski (18 January 1908 – 22 August 1974) Polish-British mathematician, philosopher, academic and author of more than eighteen scholarly books, focusing on William Blake, magic and evolution; is best known for developing a humanistic approach to science, and as the presenter and writer of the 1973 BBC television documentary series, and accompanying book The Ascent of Man, which led to his regard as "one of the world's most celebrated intellectuals". Anita Brookner (16 July 1928 – 10 March 2016) of Polish Jewish ancestry, novelist and art historian; Slade Professor of Fine Art at the University of Cambridge from 1967 to 1968; first woman to hold this visiting professorship; awarded Booker–McConnell Prize for her novel Hotel du Lac. Sam Bourne novelist pseudonym of Jonathan Freedland.
Liver function tests (LFTs or LFs), also referred to as a hepatic panel or liver panel, are groups of blood tests that provide information about the state of a patient's liver. These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin, bilirubin (direct and indirect), and others. The liver transaminases aspartate transaminase (AST or SGOT) and alanine transaminase (ALT or SGPT) are useful biomarkers of liver injury in a patient with some degree of intact liver function. Most liver diseases cause only mild symptoms initially, but these diseases must be detected early. Hepatic (liver) involvement in some diseases can be of crucial importance. This testing is performed on a patient's blood sample. Some tests are associated with functionality (e.g., albumin), some with cellular integrity (e.g., transaminase), and some with conditions linked to the biliary tract (gamma-glutamyl transferase and alkaline phosphatase). Because some of these tests do not measure function, it is more accurate to call these liver chemistries or liver tests rather than liver function tests. Several biochemical tests are useful in the evaluation and management of patients with hepatic dysfunction. These tests can be used to detect the presence of liver disease. They can help distinguish among different types of liver disorders, gauge the extent of known liver damage, and monitor the response to treatment.
==== Isoenzymes ==== Isoenzymes, or isozymes, are multiple forms of an enzyme, with slightly different protein sequence and closely similar but usually not identical functions. They are either products of different genes, or else different products of alternative splicing. They may either be produced in different organs or cell types to perform the same function, or several isoenzymes may be produced in the same cell type under differential regulation to suit the needs of changing development or environment. LDH (lactate dehydrogenase) has multiple isozymes, while fetal hemoglobin is an example of a developmentally regulated isoform of a non-enzymatic protein. The relative levels of isoenzymes in blood can be used to diagnose problems in the organ of secretion .
Sources: en.wikipedia.org
=== Non-TB conditions === Tentative evidence exists for a beneficial non-specific effect of intradermal BCG vaccination on overall mortality in low-income countries, or for its reducing other health problems including sepsis and respiratory infections when given early, with greater benefit the earlier it is used. There is also tentative evidence of intravesical (injected into the bladder) BCG providing some protection against future dementia.
Lipolysis, the removal of the fatty acid chains from the glycerol to which they are bound in their storage form as triglycerides (or fats), is carried out by lipases. These lipases are activated by high epinephrine and glucagon levels in the blood (or norepinephrine secreted by sympathetic nerves in adipose tissue), caused by declining blood glucose levels after meals, which simultaneously lowers the insulin level in the blood. Once freed from glycerol, the free fatty acids enter the blood, which transports them, attached to plasma albumin, throughout the body. Long-chain free fatty acids enter metabolizing cells (i.e. most living cells in the body except red blood cells and neurons in the central nervous system) through specific transport proteins, such as the SLC27 family fatty acid transport protein. Red blood cells do not contain mitochondria and are therefore incapable of metabolizing fatty acids; the tissues of the central nervous system cannot use fatty acids, despite containing mitochondria, because long-chain fatty acids (as opposed to medium-chain fatty acids) cannot cross the blood-brain barrier into the interstitial fluids that bathe these cells. Once inside the cell, long-chain-fatty-acid—CoA ligase catalyzes the reaction between a fatty acid molecule with ATP (which is broken down to AMP and inorganic pyrophosphate) to give a fatty acyl-adenylate, which then reacts with free coenzyme A to give a fatty acyl-CoA molecule.
=== Services sector === The two largest employers in the service sector are the Groupe Hospitalier du Havre with 4,384 staff and the City of Le Havre with 3,467 permanent employees. The city has long been home to many service companies whose activity is related to port operations: primarily the ship-owning companies and also the marine insurance companies. The headquarters of Delmas (transport and communications, 1,200 employees) and SPB (Provident Society Banking, insurance, 500 employees) have settled recently at the entrance to the city. The head office of Groupama Transport (300 employees) is also present. The transport sector is the largest economic sector in Le Havre with 15.5% of employment. Logistics occupies a large part of the population and the ISEL trains engineers in this field. Since September 2007 the ICC has welcomed local students in their first year in the relocated Europe-Asia campus of the Institute of Political Studies of Paris. Higher Education is represented by the University of Le Havre which employs 399 permanent professors and 850 lecturers as well as by engineering companies like Auxitec and SERO. There are many growth factors in the tourist industry: blue flag rating, World Heritage status from UNESCO, the label French Towns and Lands of Art and History, cruise ship development, a policy of value-creation from heritage, and the City of the Sea project. In January 2020 the city had 26 hotels with a total of 1,428 rooms. Le Havre is the seat of the Chamber of Commerce and Industry of Le Havre. It manages the Le Havre Octeville Airport.
The two substrates of this enzyme are ethyl (S)-3-hydroxyhexanoate and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are ethyl 3-oxohexanoate, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is ethyl-(S)-3-hydroxyhexanoate:NADP+ 3-oxidoreductase. This enzyme is also called 3-oxo ester (S)-reductase.
== External links == Ciliary+neurotrophic+factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P26441 (Ciliary neurotrophic factor) at the PDBe-KB.
Sources: en.wikipedia.org
In the United States, an El Niño is declared when the Climate Prediction Center, which monitors the sea surface temperatures in the Niño 3.4 region and the tropical Pacific, forecasts that the sea surface temperature will be .5 °C (0.90 °F) above average or more for the next several seasons. The Niño 3.4 region stretches from the 120th to 170th meridians west longitude astride the equator five degrees of latitude on either side, are monitored. It is approximately 3,000 kilometres (1,900 mi) to the southeast of Hawaii. The most recent three-month average for the area is computed, and if the region is more than 0.5 °C (0.9 °F) above (or below) normal for that period, then an El Niño (or La Niña) is considered in progress. In February 2026, anomalous increases in tropical sea surface temperatures caused NOAA to revise the threshold distinguishing La Niña and El Niño from each other. The new method replaces a dependency on a 30-year climate base period with the Relative Oceanic Niño Index (RONI): a comparison of the ENSO region to the global tropics. The Australian Bureau of Meteorology looks at the trade winds, Southern Oscillation Index, weather models and sea surface temperatures in the Niño 3 and 3.4 regions, before declaring an ENSO event. The Japan Meteorological Agency declares that an ENSO event has started when the average five month sea surface temperature deviation for the Niño 3 region is over 0.5 °C (0.90 °F) for six consecutive months or longer.
As a prototypical transaminase, AST relies on PLP (vitamin B6) as a cofactor to transfer the amino group from aspartate or glutamate to the corresponding ketoacid. In the process, the cofactor shuttles between PLP and the pyridoxamine phosphate (PMP) form. The amino group transfer catalyzed by this enzyme is crucial in both amino acid degradation and biosynthesis. In amino acid degradation, following the conversion of α-ketoglutarate to glutamate, glutamate subsequently undergoes oxidative deamination to form ammonium ions, which are excreted as urea. In the reverse reaction, aspartate may be synthesized from oxaloacetate, which is a key intermediate in the citric acid cycle. Two isoenzymes are present in a wide variety of eukaryotes. In humans:
==== Hemisphere effect ==== The northern and southern hemispheres have atmospheric circulation systems that are sufficiently independent of each other that there is a noticeable time lag in mixing between the two. The atmospheric 14C/12C ratio is lower in the southern hemisphere, with an apparent additional age of about 40 years for radiocarbon results from the south as compared to the north. This is because the greater surface area of ocean in the southern hemisphere means that there is more carbon exchanged between the ocean and the atmosphere than in the north. Since the surface ocean is depleted in 14C because of the marine effect, 14C is removed from the southern atmosphere more quickly than in the north. The effect is strengthened by strong upwelling around Antarctica.
1996: Insulin lispro, which was originally manufactured by Eli Lilly and Company, is granted approval. 2000: Insulin aspart, which was created by Novo Nordisk, is approved. 2000: Insulin glargine, which was developed by Sanofi-Aventis, is approved. 2004: Insulin glulisine, also developed by Sanofi-Aventis, is approved. 2005: Insulin detemir, which was formulated by Novo Nordisk, gets approval. 2015: Insulin degludec, created by Novo Nordisk, is approved. 2020: Insulin lispro-aabc, a faster insulin lispro formulation created by Eli Lilly and Company, is approved. 2021: Insulin glargine-yfgn, the first approved insulin biosimilar, which is produced by Viatris, is approved. 2021: Insulin glargine-aglr, a biosimilar produced by Eli Lilly and Company, is granted approval. 2024: Insulin icodec, the newest commercially available analogue by Novo Nordisk, gets approval. 2025: Insulin aspart-szjj, the first short-acting biosimilar, created by Viatris, is approved.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.